Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
BACKGROUND
Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health.


METHODS
To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control.


RESULTS
On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later.


CONCLUSIONS
The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.
Lin
Jiang-Tao
JT
Beijing China-Japan Friendship Hospital, People's Republic of China.
Zhang
Jian-San
JS
Su
Nan
N
Xu
Jian-Guo
JG
Wang
Nan
N
Chen
Jiang-Ting
JT
Chen
Xin
X
Liu
Yu-Xuan
YX
Gao
Hong
H
Jia
Yu-Ping
YP
Liu
Yan
Y
Sun
Rui-Hua
RH
Wang
Xu
X
Yu
Dong-Zheng
DZ
Hai
Rong
R
Gao
Qiang
Q
Ning
Ye
Y
Wang
Hong-Xia
HX
Li
Ma-Chao
MC
Kan
Biao
B
Dong
Guan-Mu
GM
An
Qi
Q
Wang
Ying-Qun
YQ
Han
Jun
J
Qin
Chuan
C
Yin
Wei-Dong
WD
Dongs
Xiao-Ping
XP
D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009500:Neutralization Tests; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology* / Q000628:therapy* / Q000821:virology; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines